Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Case Study: Treating Progressive Renal Cell Carcinoma

March 19th 2014

Second-Line Angiogenesis Inhibition in mRCC

March 19th 2014

Second-Line Treatment of Metastatic Renal Cell Carcinoma

March 19th 2014

Optimizing the Upfront Treatment of mRCC

March 19th 2014

Cytoreductive Nephrectomy in Untreated Metastatic RCC

March 19th 2014

Frontline Treatment of Poor-Risk mRCC

March 19th 2014

Treatment of Metastatic Non-Clear Cell RCC

March 19th 2014

Introduction: Multidisciplinary Frontline Treatment of mRCC

March 19th 2014

The Promise of ACOs and Bundled Payments Remains Cloudy

March 12th 2014

Evidence that demonstrates how best to implement newer value-based purchasing (VBP) programs like accountable care organizations (ACOs) and bundled payments is lacking

Dr. Salerno on the Importance of Clinical Researchers

March 12th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, discusses federal funding for research and the importance of gaining funds though private philanthropy to support clinical researchers.

Dr. Peeters on the Future of Colorectal Cancer

March 11th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.

Ellen Matloff on Oophorectomy Timing for BRCA Carriers

March 10th 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

What's Ahead for BRCA Genetic Testing and Counseling?

March 8th 2014

The US Supreme Court's landmark decision last June, mandating that an individual's genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.

Dr. Leyland-Jones on Breast Cancer Risk Assessment Tools

March 3rd 2014

Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.

Discovery Dilemma: Narrow "Superiority" Standard Is an Inferior Way to Evaluate Novel Therapies

February 27th 2014

The lack of documented superiority in a given randomized oncology trial may not indicate the absence of clinical utility but rather the presence of equivalent favorable activity for each of the two agents.

Final Thoughts on the Treatment of mCRC

February 26th 2014

Panitumumab, Regorafenib, and Ziv-aflibercept in mCRC

February 26th 2014

Third-Line Treatment Options for mCRC

February 26th 2014

First- and Second-Line Treatment of mCRC in Specific Populations

February 26th 2014

Current Trends in the Treatment of CRC

February 26th 2014